The safety of gadolinium in patients with stage 3 and 4 renal failure

Creative Commons License

Ergun I., KEVEN K., Uruc I., Ekmekci Y., Canbakan B., Erden I., ...More

NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.21, no.3, pp.697-700, 2006 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 3
  • Publication Date: 2006
  • Doi Number: 10.1093/ndt/gfi304
  • Journal Name: NEPHROLOGY DIALYSIS TRANSPLANTATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.697-700
  • Keywords: acute renal failure, chronic renal failure, contrast nephropathy, gadolinium, CONTRAST-INDUCED NEPHROPATHY, NEPHROTOXICITY, DIMEGLUMINE, ANGIOGRAPHY, MEDIA
  • Open Archive Collection: AVESIS Open Access Collection
  • Ankara University Affiliated: No

Abstract

Background. Although there is a well-documented risk of acute renal failure (ARF) with the iodinated contrast agents, intravenous gadolinium-based contrast agents are considered non-nephrotoxic and have been widely used for magnetic resonance imaging (MRI). However, debate continues regarding the safety issue of gadolinium, especially in patients with kidney failure. Therefore, we aimed to evaluate the safety of gadolinium in patients with stage 3 and 4 renal failure as well as risk factors for nephrotoxicity.